Pancreatitis on Ozempic (semaglutide 0.5-2 mg): Week-by-Week Timeline of What to Expect

What the Ozempic label says

The Ozempic label says acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists including Ozempic. It describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. The label says that suspected pancreatitis calls for discontinuation of Ozempic and appropriate management [1].

The postmarketing list includes acute and necrotizing pancreatitis, sometimes fatal, and states that frequency cannot be estimated from voluntary reports [1]. Ozempic starts at 0.25 mg for 4 weeks, then 0.5 mg; maintenance is 0.5, 1 or 2 mg, with at least 4 weeks on the current dose before each increase [1].

How often pancreatitis is reported

In the Ozempic glycemic-control trials, the label reports acute pancreatitis confirmed by adjudication in 7 Ozempic-treated patients (0.3 cases per 100 patient-years) versus 3 comparator-treated patients (0.2 cases per 100 patient-years) [1]. Those rates cover the whole trial period, not individual weeks. Separately, the frequency of voluntary postmarketing reports cannot be estimated [1].

A broader analysis is reassuring. A meta-analysis of 21 randomized trials covering 99,599 patients on GLP-1 receptor agonists found no difference in pancreatitis compared with controls [2]. A narrative review of real-world evidence in type 2 diabetes and obesity populations reported frequent gastrointestinal disturbances, as in trials, but no clear increase in severe events such as pancreatitis [3].

Abdominal pain reported with Ozempic

In the Ozempic pooled placebo-controlled trials in type 2 diabetes (262 on placebo, 260 on 0.5 mg, 261 on 1 mg, mean 32.9 weeks), abdominal pain was reported by 4.6% on placebo, 7.3% on 0.5 mg and 5.7% on 1 mg; nausea by 6.1%, 15.8% and 20.3%; and vomiting by 2.3%, 5% and 9.2% [1]. These are general reaction rates, not pancreatitis rates; the label says pancreatitis pain may or may not come with nausea or vomiting [1].